M. Shamim

The Tumour Immune Microenvironment in Glioblastoma: Implications for Immunotherapy Failure and Future Directions

Glioblastoma accounts for 14.5% of all central nervous system (CNS) tumours. Current immunotherapeutic strategies include surgery, radiotherapy, and chemotherapy, with an increased focus on checkpoint inhibitors and CAR-T cell therapy. However, these have demonstrated limited clinical effectiveness due to the tumour’s...

Surgical outcomes of primary pediatric spinal cord tumors: A retrospective cohort

Background: Pediatric primary spinal cord tumors are rare, accounting for approximately 6% of central nervous system neoplasms. Most published data come from high-income countries (HICs) with access to early diagnosis, intraoperative monitoring, and specialized neuro-oncology units. In low- and middle-income countries...

Clinical Outcomes and Prognostic Factors Following Surgery for Supratentorial Intraventricular Tumours: A 15-year Experience.

Immunotherapy in Glioblastoma: Why promising strategies fail to improve survival

Immunotherapy has transformed the management of several extracranial malignancies; however, its efficacy in GBM has been limited. Large clinical trials evaluating immune checkpoint inhibitors have failed to demonstrate meaningful survival benefit in newly diagnosed and recurrent GBM. Other modalities, including dendrit...